Markets:

Overview

News

Currencies

International

Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

84.86 -1.64 (-1.90%)

Streaming Delayed Price Updated: 3:14 PM EST, Feb 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Analyst Ratings for Ionis Pharmaceuticals ↗

September 09, 2022

Over the past 3 months, 6 analysts have published their opinion on Ionis Pharmaceuticals (NASDAQ:IONS) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary ↗

September 07, 2022

Via Benzinga

Praxis Precision Outlines Upcoming Plans For Pediatric Epilepsy Programs ↗

September 07, 2022

Via Benzinga

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful ↗

August 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Ionis Pharma Extends Breakout; Biotech Restates Guide Despite Quarterly Miss ↗

August 09, 2022

The guidance stayed intact despite a wide second-quarter flop.

Via Investor's Business Daily

Where Ionis Pharmaceuticals Stands With Analysts ↗

July 26, 2022

Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings within the last quarter:

Via Benzinga

Recap: Ionis Pharmaceuticals Q1 Earnings ↗

May 04, 2022

Ionis Pharmaceuticals (NASDAQ:IONS) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Ionis Pharmaceuticals: Q2 Earnings Insights ↗

August 09, 2022

Ionis Pharmaceuticals (NASDAQ:IONS) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Moderna, PayPal And Some Other Big Gainers From Wednesday ↗

August 04, 2022

U.S. stocks closed higher on Wednesday, with the Dow Jones gaining more than 400 points. Here is the list of some big stocks moving higher in the previous session.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

July 29, 2022

Good morning, trader! It's time to start off Friday with a breakdown of the biggest pre-market stock movers traders need to know about!

Via InvestorPlace

This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday ↗

August 04, 2022

Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume.

Via Benzinga

Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session ↗

August 03, 2022

Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday.

Via Benzinga

Recap Of Thursday's Biotech Catalysts - End of The Day Summary ↗

July 28, 2022

Via Benzinga

Ionis Reveals Positive Results From Anti-Blood Clot Therapy In Hemodialysis ↗

July 28, 2022

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced positive topline results of the Phase 2b clinical trial of fesomersen in patients with end-stage renal disease (ESRD) on hemodialysis.

Via Benzinga

FDA Accepts Biogen's Submission For Neurodegenerative Disease Drug Under Priority Review ↗

July 26, 2022

The U.S. Food and Drug Administration (FDA) has accepted Biogen’s (NASDAQ: BIIB) New Drug Application (NDA) for its lead asset Tofersen for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis...

Via Benzinga

Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate ↗

July 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

7 Undervalued Biotech Stocks to Buy Before They Boom ↗

July 25, 2022

Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy.

Via InvestorPlace

Recap of Wednesday's Biotech Catalysts - End of The Day Summary ↗

July 20, 2022

Via Benzinga

The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death ↗

July 11, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

7 Best Biotech Stocks to Buy in July 2022 ↗

July 08, 2022

The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict.

Via InvestorPlace

Cathie Wood's Ark Invest Sheds $35M In 3D Printing Company Stratasys — What It Bought Instead ↗

July 06, 2022

As the market reopened following the long July 4 weekend, Cathie Wood-run Ark Invest made some portfolio moves, notable among which is the offloading of a huge chunk of Stratasys Ltd. (NASDAQ: SSYS)...

Via Benzinga

EXCLUSIVE: Has Biotech Bottomed? NYSE Executive Floor Director Says Biogen And These 3 Stocks Look Poised To Outperform ↗

June 30, 2022

Markets continue to trend lower amid rising inflation and Fed uncertainty, but one New York Stock Exchange floor director says the bottom may be in for a couple of beaten-down sectors.

Via Benzinga

Recap of Tuesday's Biotech Catalysts - End of the Day Summary ↗

June 21, 2022

Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid...

Via Benzinga

The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial ↗

June 21, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026

June 22, 2022

Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It...

Via FinancialNewsMedia

AstraZeneca - Ionis Eplontersen Achieves Positive Data In Rare Disease Trial ↗

June 21, 2022

Via Benzinga

5 Cathie Wood Stocks to Buy in June ↗

June 09, 2022

These are the five best Cathie Wood stocks to buy in June. EXAS, IONS, KTOS, TRMB, and PATH can make excellent investments.

Via InvestorPlace

Cathie Wood Is Selling Gene Editing Stocks. Here’s Why. ↗

June 02, 2022

Cathie Wood has recently sold off large positions in several gene-editing stocks from her ARKG ETF. What's behind Wood's latest moves?

Via InvestorPlace

Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗

May 20, 2022

Benzinga Pro data, Ionis Pharmaceuticals (NASDAQ:IONS) reported Q1 sales of $142.00 million. Earnings fell to a loss of $65.17 million, resulting in a 129.01% decrease from last quarter.

Via Benzinga

What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals ↗

May 09, 2022

Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings:

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.